These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28342234)

  • 1. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
    Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
    J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Sakkas LI
    Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.
    Taniguchi T; Miyagawa T; Tamaki Z; Nakamura K; Yamashita T; Saigusa R; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Tada Y; Sugaya M; Kadono T; Sato S; Asano Y
    Arch Dermatol Res; 2017 Dec; 309(10):833-842. PubMed ID: 29038846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
    Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
    Asano Y
    Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis.
    Jiang Z; Chen C; Yang S; He H; Zhu X; Liang M
    J Dermatol Sci; 2021 Oct; 104(1):63-73. PubMed ID: 34556381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.
    Mostmans Y; Cutolo M; Giddelo C; Decuman S; Melsens K; Declercq H; Vandecasteele E; De Keyser F; Distler O; Gutermuth J; Smith V
    Autoimmun Rev; 2017 Aug; 16(8):774-786. PubMed ID: 28572048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma endothelial microparticles reflect the extent of capillaroscopic alterations and correlate with the severity of skin involvement in systemic sclerosis.
    Michalska-Jakubus M; Kowal-Bielecka O; Smith V; Cutolo M; Krasowska D
    Microvasc Res; 2017 Mar; 110():24-31. PubMed ID: 27889559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
    Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
    Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
    Zacay G; Levy Y
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
    Shima Y
    Cells; 2021 May; 10(5):. PubMed ID: 34064515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
    Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
    Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis.
    Pizzorni C; Giampetruzzi AR; Mondino C; Facchiano A; Abeni D; Paolino S; Ruaro B; Smith V; Sulli A; Cutolo M
    Microvasc Res; 2017 May; 111():20-24. PubMed ID: 27989404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
    Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
    Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells.
    Lee BR; Kwon BE; Hong EH; Shim A; Song JH; Kim HM; Chang SY; Kim YJ; Kweon MN; Youn JI; Ko HJ
    Cancer Lett; 2016 Oct; 381(1):156-64. PubMed ID: 27431309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
    Saigusa R; Asano Y; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    Br J Dermatol; 2016 Feb; 174(2):338-47. PubMed ID: 26399195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
    Shima Y
    Mod Rheumatol; 2019 Mar; 29(2):294-301. PubMed ID: 30561237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.